Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Atherosclerosis × Hydroxymethylglutaryl-CoA Reductase Inhibitors × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 3 Prostatic Neoplasms 2 Carcinoma, Hepatocellular 2 Breast Neoplasms 2 Ovarian Neoplasms 1 Ototoxicity 1 Heart Failure 1 Endometrial Neoplasms 1 Endometrial Hyperplasia 1 Cardiovascular Diseases 1 Cardiotoxicity 1 Atherosclerosis 1

Interventions

Exercise 2 evolocumab 1 Standard of Care 1 Rosuvastatin Calcium 1 Hydroxymethylglutaryl-CoA Reductase Inhibitors 1 Blood Specimen Collection 1 Atorvastatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05976893 2023-08-04

Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer

Xinjiang Medical University

Phase 4 Unknown

Neoplasms, Atherosclerosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡